You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Creating Research Files from CMS Data for Integration with Survey Data

    SBC: ACUMEN LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This STTR proposal to the National Institute on Aging (NIA) requests funding to expand the capabilities of the Medicare Research Information Center (MedRIC) recently established by Acumen LLC with earlier support from NIA. The purpose of MedRIC is to facilitate the acquisition and linking of administrative data from the Centers for Medicare and Medicaid Service ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  2. CELLULAR PSYCHOPHARMACOLOGICAL MONITORING SYSTEM

    SBC: Plastics One, Inc.            Topic: N/A

    N/A

    STTR Phase I 1998 Department of Health and Human Services
  3. A novel platelet inhibitor from bloodfeeding hookworms

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Thromboembolic disease is a major cause of morbidity and mortality in the developed world. Because platelets play a critical role in the activation and propagation of thrombosis, they represent important targets for new anti-thrombotic drugs. A potent inhibitor of human platelet function has been isolated from the bloodfeeding hookworm, Ancylostoma caninum. ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  4. Aerosolized hyaluronic acid as a treatment for emphysema

    SBC: EXHALE THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease afflicts 12-14 million people in the US and in an advanced form, emphysema, disables 2 million and ultimately leads to death. No approved, existing treatment can arrest emphysema's progressive destruction of the lung. Exhale Therapeutics, Inc intends to develop and commercialize aeros ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  5. Immune Attack: Simulation Game for Adolescent Education

    SBC: SIMQUEST INTERNATIONAL, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This research project will develop an engaging game for high school students using simulation of immune cells in the human body fighting infection. The approach combines visually stunning 3D graphics and advanced training technologies including automated case scenario generation, intelligent tutoring, automated debriefing, live conferencing, and performance ass ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  6. Bounding generalization risk for Deep Neural Networks

    SBC: Euler Scientific            Topic: NGA20A001

    Deep Neural Networks have become ubiquitous in the modern analysis of voluminous datasets with geometric symmetries. In the field of Particle Physics, experiments such as DUNE require the detection of particle signatures interacting within the detector, with analyses of over a billion 3D event images per channel each year; with typical setups containing over 150,000 different channels.  In an ...

    STTR Phase I 2020 Department of DefenseNational Geospatial-Intelligence Agency
  7. Development of a novel whole blood coagulation assay

    SBC: HEMODYNE            Topic: N/A

    The inability to adequately monitor the effects of newer, potent anticoagulants is increasingly apparent. These powerful drugs have a very narrow therapeutic window. This is especially true in high-risk populations such as those with hepatic and renal dysfunction. Conventional monitoring parameters (i.e., PT, aPTT, INR) do not adequately measure or predict efficacy or toxicity for many of these ne ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  8. Heterologous Production of Eleutherobin Precursors

    SBC: AMYRIS BIOTECHNOLOGIES            Topic: N/A

    DESCRIPTION (provided by applicant): Terpenoids are a diverse class of natural compounds with equally diverse and potent bioactivities. Because the practical use of terpenoids hinges on the ability to extract or synthesize these compounds, only the most abundant or easily synthesized compounds have been commercially developed. The long-term goal of this Small Business Technology Transfer Phase I p ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  9. New Topical Therapies for Psoriasis

    SBC: BETHESDA PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Psoriasis is a common, inflammatory disease of the skin characterized by hyperproliferation of keratinocytes. A variety of antipsoriatic therapies are available, however, due to problems with side effects and variability in clinical response, intense clinical and commercial interest remains in the development of new treatments. In the current studies, we will ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  10. PET Reagents for Normal and Tumor Tissue Hypoxia

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Disruption of O2 gradients in normal tissues creates major medical problems including cardiovascular disease, stroke, diabetes, liver and kidney damage and organ transplant failure. Steep O2 gradients in tumors protect tumor cells from cytotoxic therapies and create more aggressive tumors. Measurements of O2 gradients are cle ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government